Skip to main content
SpringerLink
Log in

Enterococcus: Antimicrobial Resistance in Enterococci Epidemiology, Treatment, and Control

  • Chapter
Antimicrobial Drug Resistance

Part of the book series: Infectious Disease ((ID))

Enterococci are Gram-positive, facultative anaerobic cocci that are morphologically similar to streptococci on gram strain (1, 2). The normal habitat of these microorganisms is the gastrointestinal tract of human and other mammals, although they can be isolated from the oropharynx, female genital tract, and skin. Most recently, 36 species of enterococci have been described; however, 26 have been associated with human infection (2–4). Enterococcus faecalis is the most common human pathogen, but Enterococcus faecium has become increasingly prevalent in hospital-acquired infections. All the other enterococcal species together constitute less than 5% of enterococcal infections (2–4). These other species associated with human infections include Enterococcus gallinarum, Enterococcus casselifl avus, Enterococcus avium, Enterococcus cecorum, Enterococcus durans, Enterococcus hirae, Enterococcus malodoratus, Enterococcus mundtii, Enterococcus pseudoavium, and Enterococcus raffi nosus (2–11).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Murray BE. The life and times of the Enterococcus. Clin Microbiol Rev 1990;3:46–65

    PubMed  CAS  Google Scholar 

  2. Facklam RR, Collins MD. Identification of Enterococcus species isolated from human infections by a conventional test scheme. J Clin Microbiol 1989;27:731–734

    PubMed  CAS  Google Scholar 

  3. Gordon S, Swenson JM, Hill BC, et al. Antimicrobial susceptibility patterns of common and unusual species of entero-cocci causing infections in the United States. J Clin Microbiol 1992;30:2373–2378

    PubMed  CAS  Google Scholar 

  4. Ruoff KL, de la Maza L, Murtagh MJ, Spargo JD, Ferraro MJ. Species identities of enterococci isolated from clinical specimens. J Clin Microbiol 1990;28:435–437

    PubMed  CAS  Google Scholar 

  5. De Baere T, Claeys G, Verschraegen G, et al. Continuous ambulatory peritoneal dialysis peritonitis due to Enterococcus cecorum. J Clin Microbiol 2000;38:3511–3512

    PubMed  Google Scholar 

  6. Gullberg RM, Homann SR, Phair JP. Enterococcal bacteremia:analysis of 75 episodes. Rev Infect Dis 1989;11:74–85

    PubMed  CAS  Google Scholar 

  7. Hsueh PR, Teng LJ, Chen YC, Yang PC, Ho SW, Luh KT. Recurrent bacteremic peritonitis caused by Enterococcus cecorum in a patient with liver cirrhosis. J Clin Microbiol 2000;38:2450–2452

    PubMed  CAS  Google Scholar 

  8. Mellman RL, Spisak GM, Burakoff R. Enterococcus avium bacteremia in association with ulcerative colitis. Am J Gast 1992;87:337–338

    Google Scholar 

  9. Patel R, Keating MR, Cockerill FR III, Steckelberg JM. Bacteremia due to Enterococcus avium. Clin Infect Dis 1993;17:1006–1011

    PubMed  CAS  Google Scholar 

  10. Pérez Mato S, Robinson S, Bégué RE. Vancomycin-resistant Enterococcus faecium meningitis successfully treated with chlo-ramphenicol. Pediatr Infect Dis J 1999;18:483–484

    Article  PubMed  Google Scholar 

  11. Van Goethem GF, Louwagie BM, Simoens MJ, Vandeven JM, Verhaegen JL, Boogaerts MA. Enterococcus casseliflavus septicaemia in a patient with acute myeloid leukaemia. Eur J Clin Microbiol Infect Dis 1994;13:519–520

    Article  PubMed  Google Scholar 

  12. Zervos MJ, Kauffman CA, Therasse P, Bergman A, Mikesell TS, Schaberg DR. Nosocomial infection caused by gentamicin resistant Streptococcus faecalis:an epidemiologic study. Ann Intern Med 1987;106:687–691

    PubMed  CAS  Google Scholar 

  13. Fridkin SK, Edwards JR, Courval JM, et al. The effect of van-comycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units. Ann Int Med 2001;135:175–183

    CAS  Google Scholar 

  14. Vergis EN, Hayden MK, Chow JW, et al. Determinants of van-comycin resistance and mortality rates in enterococcal bacter-emia:a prospective multicenter study. Ann Intern Med 2001;135:484–492

    PubMed  CAS  Google Scholar 

  15. Byers KE, Anglim AM, Anneski CJ, et al. A hospital epidemic of vancomycin-resistant Enterococcus:risk factors and control. Infect Control Hosp Epidemiol 2001;22:140–147

    Article  PubMed  CAS  Google Scholar 

  16. Falk PS, Winnike J, Woodmansee C, Desai M, Mayhall CG. Outbreak of vancomycin-resistant enterococci in a burn unit. Infect Control Hosp Epidemiol 2000;21:575–582

    Article  PubMed  CAS  Google Scholar 

  17. Montecalvo MA, Jarvis WR, Uman J, et al. Infection-control measures reduce transmission of vancomycin-resistant enterococci in an endemic setting. Ann Intern Med 1999;131:269–272

    PubMed  CAS  Google Scholar 

  18. Morris JG Jr, Shay DK, Hebden JN, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin. Ann Intern Med 1995; 123:250–259

    PubMed  CAS  Google Scholar 

  19. Malani PN, Thal L, Donabedian SM, et al. Molecular analysis of vancomycin-resistant Enterococcus faecalis from Michigan hospitals during a 10 year period. J Antimicrob Chemother 2002;49(5):841–843

    Article  PubMed  CAS  Google Scholar 

  20. Thal L, Donabedian S, Robinson-Dunn B, et al. Molecular analysis of glycopeptide-resistant Enterococcus faecium isolates collected from Michigan hospitals over a 6-year period. J Clin Microbiol 1998;36(11):3303–3308

    Google Scholar 

  21. Diaz-Granados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections:a meta-analysis. Clin Infect Dis 2005;41:327–333

    Article  Google Scholar 

  22. Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. Clin Microbiol Rev 2000;13:686–707

    Article  PubMed  CAS  Google Scholar 

  23. Edmond MB, Ober JF, Weinbaum DL, et al. Vancomycin-resistant Enterococcus faecium bacteremia:risk factors for infection. Clin Infect Dis 1995; 20:1126–1133

    PubMed  CAS  Google Scholar 

  24. Hayden MK. Insights into the epidemiology and control of infection with vancomycin-resistant enterococci. Clin Infect Dis 2000;31:1058–1065

    Article  PubMed  CAS  Google Scholar 

  25. Tornieporth NG, Roberts RB, John J, Hafner A, Riley LW. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin Infect Dis 1996;23:767–772

    PubMed  CAS  Google Scholar 

  26. Zaas AK, Song X, Tucker P, Perl TM. Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci. Clin Infect Dis 2002;35:1139–1146

    Article  PubMed  Google Scholar 

  27. Carmeli Y, Eliopoulos GM, Samore MH. Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus. Emerg Infect Dis 2002;8:802–807

    PubMed  CAS  Google Scholar 

  28. Harbarth S, Cosgrove S, Carmeli Y. Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci. Antimicrob Agents Chemother 2002;46:1619–1628

    Article  PubMed  CAS  Google Scholar 

  29. Padiglione AA, Wolfe R, Grabsch EA, et al. Risk factors for new detection of vancomycin-resistant enterococci in acute-care hospitals that employ strict infection control procedures. Antimicrob Agents Chemother 2003;47:2492–2498

    Article  PubMed  CAS  Google Scholar 

  30. Stiefel U, Paterson DL, Pultz NJ, Gordon SM, Aron DC, Donskey CJ. Effect of the increasing use of piperacillin/tazobactam on the incidence of vancomycin-resistant enterococci in four academic medical centers. Infect Control Hosp Epidemiol 2004;25:380–383

    Article  PubMed  Google Scholar 

  31. DiNubile MJ, Chow JW, Satishchandran V, et al. Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin–tazobactam therapy for intraabdom-inal infections. Antimicrob Agents Chemother 2005;49:3217–3221

    Article  PubMed  CAS  Google Scholar 

  32. Donskey CJ, Chowdhry TK, Hecker MT, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med 2000;343:1925–1932

    Article  PubMed  CAS  Google Scholar 

  33. Stiefel U, Pultz NJ, Helfand MS, Donskey CJ. Increased susceptibility to vancomycin-resistant Enterococcus intestinal colonization persists after completion of anti-anaerobic antibiotic treatment in mice. Infect Control Hosp Epidemiol 2004;25:373–379

    Article  PubMed  Google Scholar 

  34. Carmeli Y, Samore MH, Huskins WC. The association between antecedent vancomycin treatment and hospital-acquired vanco-mycin-resistant enterococci:a meta-analysis. Arch Intern Med 1999;159:2461–2468

    Article  PubMed  CAS  Google Scholar 

  35. Donabedian SM, Thal LA, Hershberger E, et al. Molecular characterization of gentamicin-resistant Enterococci in the United States:evidence of spread from animals to humans through food. J Clin Microbiol 2003;41:1109–1113

    Article  PubMed  CAS  Google Scholar 

  36. Hershberger E, Donabedian S, Konstantinou K, Zervos MJ. Quinupristin—dalfopristin resistance in gram-positive bacteria:mechanism of resistance and epidemiology. Clin Infect Dis 2004;38:92–98

    Article  PubMed  CAS  Google Scholar 

  37. Hershberger E, Oprea SF, Donabedian SM, et al. Epidemiology of antimicrobial resistance in enterococci of animal origin. J Antimicrob Chemother 2005;55:127–130

    Article  PubMed  CAS  Google Scholar 

  38. Jensen VF, Neimann J, Hammerum AM, Molbak K, Wegener HC. Does the use of antibiotics in food animals pose a risk to human health? An unbiased review? J Antimicrob Chemother 2004;54:274–275

    Article  PubMed  CAS  Google Scholar 

  39. Vergis EN, Shankar N, Chow JW, et al. Association between the presence of enterococcal virulence factors gelatinase, hemolysin, and enterococcal surface protein and mortality among patients with bacteremia due to Enterococcus faecalis. Clin Infect Dis 2002;35:570–575

    Article  PubMed  CAS  Google Scholar 

  40. Gilmore MS, Coburn PS, Nallapareddy SR, Murray BE. Enterococcal virulence. In:Gilmore MS, ed. The Enterococci. Pathogenesis, Molecular Biology, and Antibiotic Resistance. Washington, DC:ASM Press, 2002:301–354

    Google Scholar 

  41. Cercenado E, Eliopoulos GM, Wennersten CB, Moellering RC Jr. Influence of high-level gentamicin resistance and beta-hemolysis on susceptibility of enterococci to the bactericidal activities of ampicillin and vancomycin. Antimicrob Agents Chemother 1992;36:2526–2528

    PubMed  CAS  Google Scholar 

  42. Moellering RC Jr, Weinberg AN. Studies on antibiotic syner-gism against enterococci. II. Effect of various antibiotics on the uptake of 14C-labelled streptomycin by enterococci. J Clin Invest 1971;50:2580–2584

    Article  PubMed  CAS  Google Scholar 

  43. Patterson JE, Zervos MJ. High-level gentamicin resistance in ente-rococci:epidemiology, microbiology and genetic basis. Rev Infect Dis 1990;12:644–652

    PubMed  CAS  Google Scholar 

  44. Arduino RC, Murray BE. Enterococci:antimicrobial resistance. In:Mandell GL, Douglas RG, Bennett JE, eds. Update to Principles and Practice of Infectious Diseases. New York:Churchill Livingstone Inc, 1993:3–15

    Google Scholar 

  45. Ferretti JJ, Gilmore KS, Courvalin P. Nucleotide sequence analysis of the gene specifying the bifunctional 6′-aminoglycoside acetyl-transferase 2′-aminoglycoside phosphotransferase enzyme in Streptococcus faecalis and identification and cloning of gene regions specifying the two activities. J Bacteriol 1986;167:631–638

    PubMed  CAS  Google Scholar 

  46. Eliopoulos GM, Farber BF, Murray BE, Wennersten C, Moellering RC Jr. Ribosomal resistance of clinical enterococ-cal isolates to streptomycin. Antimicrob Agents Chemother 1984;25:398–399

    PubMed  CAS  Google Scholar 

  47. Krogstad DJ, Korfhagen TR, Moellering RC Jr, et al. Aminoglycoside-inactivating enzymes in clinical isolates of Streptococcus faecalis:an explanation for antibiotic synergism. J Clin Invest 1978;62:480–486

    Article  PubMed  CAS  Google Scholar 

  48. Ounissi H, Courvalin P. Appendix B. Nucleotide sequences of strepto-coccal genes. In:Ferretti JJ, Curtis R III, eds. Streptococcal Genetics. Washington, DC. American Society for Microbiology, 1987:275

    Google Scholar 

  49. Coque TM, Arduino RC, Murray BE. High-level resistance to aminoglycosides:comparison of community and nosocomial fecal isolates of enterococci. Clin Infect Dis 1995;20:1048–1051

    PubMed  CAS  Google Scholar 

  50. Silverman J, Thal LA, Perri MB, Bostic G, Zervos MJ. Epidemiologic evaluation of antimicrobial resistance in community acquired enterococci. J Clin Microbiol 1998;36:830–832

    PubMed  CAS  Google Scholar 

  51. Watanakunakorn C. Rapid increase in the prevalence of high-level aminoglycoside resistance among enterococci isolated from blood cultures during 1989–1991. J Antimicrob Chemother 1992;30:289–293

    Article  PubMed  CAS  Google Scholar 

  52. Moellering RC Jr, Murray BE, Schoenbaum SC, Adler J, Wennersten CB. A novel mechanism of resistance to penicillin–gentamicin syn-ergism in Streptococcus faecalis. J Infect Dis 1980;141:81–86

    PubMed  CAS  Google Scholar 

  53. Hayden M, Koenig GI, Trenholme GM. Bactericidal activities of antibiotics against vancomycin-resistant Enterococcus faecium blood isolates and synergistic activities of combinations. Antimicrob Agents Chemother 1994;38:1225–1229

    PubMed  CAS  Google Scholar 

  54. Chow JW, Zervos MJ, Lerner SA, et al. A novel gentamicin resistance gene in Enterococcus. Antimicrob Agents Chemother 1997;41:511–514

    PubMed  CAS  Google Scholar 

  55. Chow JW, Donabedian SM, Clewell DB, Sahm DF, Zervos MJ. In vitro susceptibility and molecular analysis of gentamicin-resist-ant enterococci. Diagn Microbiol Infect Dis 1998;32:141–146

    Article  PubMed  CAS  Google Scholar 

  56. Tsai SF, Zervos MJ, Clewell DB, Donabedian SM, Sahm DF, Chow JW. A new high-level gentamicin resistance gene, aph(2')-Id, in Enterococcus spp. Antimicrob Agents Chemother 1998;42:1229–1232

    PubMed  CAS  Google Scholar 

  57. Al-Obeid S, Gutmann L, Williamson R. Modification of penicillin-binding proteins of penicillin-resistant mutants of different species of enterococci. J Antimicrob Chemother 1990;26:613–618

    Article  PubMed  CAS  Google Scholar 

  58. Fontana R, Aldegheri M, Ligozzi M, Lopez H, Sucari A, Satta G. Overproduction of a low-affinity penicillin-binding protein and high-level ampicillin resistance in Enterococcus faecium. Antimicrob Agents Chemother 1994;38:1980–1983

    PubMed  CAS  Google Scholar 

  59. Grayson ML, Eliopoulos GM, Wennersten CB, et al. Increasing resistance to beta-lactam antibiotics among clinical isolates of Enterococcus faecium:a 22-year review at one institution. Antimicrob Agents Chemother 1991;35:2180–2184

    PubMed  CAS  Google Scholar 

  60. Ligozzi M, Pittaluga F, Fontana R. Identification of a genetic element (psr) which negatively controls expression of Enterococcus hirae penicillin-binding protein 5. J Bacteriol 1993;175:2046–2051

    PubMed  CAS  Google Scholar 

  61. Ligozzi M, Pittaluga F, Fontana R. Modification of penicillin-binding protein 5 associated with high-level ampicillin resistance in Enterococcus faecium. Antimicrob Agents Chemother 1996;40:354–357

    PubMed  CAS  Google Scholar 

  62. Signoretto C, Boaretti M, Canepari P. Cloning, sequencing and expression in Escherichia coli of the low-affinity penicillin-binding protein of Enterococcus faecalis. FEMS Microbiol Lett 1994;123:99–106

    Article  PubMed  CAS  Google Scholar 

  63. Bush LM, Calmon J, Cherney CL, et al. High-level penicillin resistance among isolates of enterococci. Ann Intern Med 1989;110:515–520

    PubMed  CAS  Google Scholar 

  64. Torres C, Tenorio C, Lantero M, Gastañares MJ, Baquero F. High-level penicillin resistance and penicillin–gentamicin synergy in Enterococcus faecium. Antimicrob Agents Chemother 1993;37:2427–2431

    PubMed  CAS  Google Scholar 

  65. Arthur M, Courvalin P. Genetics and mechanisms of glycopep-tide resistance in enterococci. Antimicrob Agents Chemother 1993;37:1563–1571

    PubMed  CAS  Google Scholar 

  66. Leclercq R, Courvalin P. Resistance to glycopeptides in entero-cocci. Clin Infect Dis 1997;24:545–556

    PubMed  CAS  Google Scholar 

  67. Alam MR, Donabedian S, Brown W, et al. Heteroresistance to vancomycin in Enterococcus faecium. J Clin Microbiol 2001;39:3379–3381

    Article  PubMed  CAS  Google Scholar 

  68. Navarro F, Courvalin P. Analysis of genes encoding d-alanine-d-alanine ligase-related enzymes in Enterococcus casseliflavus and Enterococcus flavescens. Antimicrob Agents Chemother 1994;38:1788–1793

    PubMed  CAS  Google Scholar 

  69. Reynolds PE, Snaith HA, Maguire AJ, Dutka-Malen S, Courvalin P. Analysis of peptidoglycan precursors in vancomycin-resistant Enterococcus gallinarum BM4174. Biochem J 1994;301:5–8

    PubMed  CAS  Google Scholar 

  70. Yao JDC, Thauvin-Eliopoulos C, Eliopoulos GM, Moellering RC Jr. Efficacy of teicoplanin in two dosage regimens for experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin. Antimicrob Agents Chemother 1990;34:827–830

    PubMed  CAS  Google Scholar 

  71. Aslangul E, Baptista M, Fantin B, et al. Selection of glyc-opeptide-resistant mutants of VanB-type Enterococcus faecalis BM4281 in vitro and in experimental endocarditis. J Infect Dis 1997;175:598–605

    PubMed  CAS  Google Scholar 

  72. Hayden MK, Trenholme GM, Schultz JE, Sahm DF. In vivo development of teicoplanin resistance in a VanB Enterococcus faecium isolate. J Infect Dis 1993;167:1224–1227

    PubMed  CAS  Google Scholar 

  73. Moellering RC Jr. Emergence of Enterococcus as a significant pathogen. Clin Infect Dis 1992;14:1173–1178

    PubMed  Google Scholar 

  74. Raymond NJ, Henry J, Workowski KA. Enterococcal arthritis:case report and review. Clin Infect Dis 1995;21:516–522

    PubMed  CAS  Google Scholar 

  75. Graninger W, Ragette R. Nosocomial bacteremia due to Enterococcus faecalis without endocarditis. Clin Infect Dis 1992;15:49–57

    PubMed  CAS  Google Scholar 

  76. Maki DG, Agger WA. Enterococcal bacteremia:clinical features, the risk of endocarditis, and management. Medicine (Baltimore) 1988;67:248–269

    Article  CAS  Google Scholar 

  77. Hoge CW, Adams J, Buchanan B, Sears SD. Enterococcal bacteremia:to treat or not to treat, a reappraisal. Rev Infect Dis 1991;13:600–605

    PubMed  CAS  Google Scholar 

  78. Noskin GA, Peterson LR, Warren JR. Enterococcus faecium and Enterococcus faecalis bacteremia:acquisition and outcome. Clin Infect Dis 1995;20:296–301

    PubMed  CAS  Google Scholar 

  79. Patterson JE, Sweeney AH, Simms M, et al. An analysis of 110 serious enterococcal infections:epidemiology, antibiotic susceptibility, and outcome. Medicine (Baltimore) 1995;74:191–200

    Article  CAS  Google Scholar 

  80. Murray BE. Beta-lactamase-producing enterococci. Antimicrob Agents Chemother 1992;36:2355–2359

    PubMed  CAS  Google Scholar 

  81. Murray BE, Singh KV, Markowitz SM, et al. Evidence for clonal spread of a single strain of beta-lactamase-producing Enterococcus (Streptococcus) faecalis to six hospitals in five states. J Infect Dis 1991;163:780–785

    PubMed  CAS  Google Scholar 

  82. Patterson JE, Masecar B, Zervos MJ. Characterization and comparison of two penicillinase-producing strains of Streptococcus faecalis. Antimicrob Agents Chemother 1988;32:122–123

    PubMed  CAS  Google Scholar 

  83. Murray BE, Singh K V, Markowitz SM, Lopardo HA, Patterson JE, Zervos MJ, Rubeglio E, Eliopoulos G, Rice LB, Goldstein FW, Caputo G, Nasnas R, Moore LS, Wong ES, Weinstock G. Evidence for clonal spread of a single strain of beta-lactamase producing Enterococcus faecalis to five hospitals in four states. J Infect Dis 1991;163:780–785

    PubMed  CAS  Google Scholar 

  84. Auckenthaler R, Wilson WR, Wright AJ, Washington JA II, Durack DT, Geraci JE. Lack of an in vivo and in vitro bactericidal activity of N-formimidoyl thienamycin against enterococci. Antimicrob Agents Chemother 1982;22:448–452

    PubMed  CAS  Google Scholar 

  85. Eliopoulos GM, Eliopoulos CT. Therapy of enterococcal infections. Eur J Clin Microbiol Infect Dis 1990;9:118–126

    Article  PubMed  CAS  Google Scholar 

  86. Scheld WE, Keeley JM. Imipenem therapy of experimental Staphylococcus aureus and Streptococcus faecalis endocarditis. J Antimicrob Chemother 1983;12(Suppl D):65–78

    PubMed  CAS  Google Scholar 

  87. Fang G, Brennen C, Wagener M, et al. Use of ciprofloxacin versus use of aminoglycoside for therapy of complicated urinary tract infection:prospective, randomized clinical and pharmacokinetic study. Antimicrob Agents Chemother 1991;35:1849–1855

    PubMed  CAS  Google Scholar 

  88. Zervos MJ, Bacon AE III, Patterson JE, Schaberg DR, Kauffman CA. Enterococcal superinfection in patients treated with ciprofloxacin. J Antimicrob Chemother 1988;21:113–115

    Article  PubMed  CAS  Google Scholar 

  89. Perri MB, Hershberger E, Ionescu M, Lauter C, Zervos MJ. In vitro susceptibility of vancomycin-resistant enterococci (VRE) to fosfomycin. Diagn Microbiol Infect Dis 2002;42(4):269–271

    Article  PubMed  CAS  Google Scholar 

  90. Taylor SE, Paterson DL, Yu VL. Treatment options for chronic prostatitis due to vancomycin-resistant Enterococcus faecium. Eur J clin Microbiol Infect Dis 1998;17:798–800

    Article  PubMed  CAS  Google Scholar 

  91. Cooper GS, Shlaes DM, Jacobs MR, Salata RA. The role of Enterococcus in intraabdominal infections:case control analysis. Infect Dis Clin Pract 1993;2:332–339

    Article  Google Scholar 

  92. Eliopoulos GM. Aminoglycoside resistant enterococcal endocarditis. Infect Dis Clin N Am 1993;7:117–133

    CAS  Google Scholar 

  93. Francioli P. Antibiotic treatment of streptococcal and enterococcal endocarditis:an overview. Eur Heart J 1995;16 (Suppl B):75–79

    PubMed  Google Scholar 

  94. Konstantinov IE, Zehr KJ. Aortic root replacement in a patient with vancomycin-resistant Enterococcus faecium endocarditis and leukemia. Chest 2001;120:1744–1746

    Article  PubMed  CAS  Google Scholar 

  95. Mandell GL, Kaye D, Levison ME, Hook EW. Enterococcal endocarditis:an analysis of 38 patients observed at the New York Hospital-Cornell Medical Center. Arch Intern Med 1970;125:258–264

    Article  PubMed  CAS  Google Scholar 

  96. Megran DW. Enterococcal endocarditis. Clin Infect Dis 1992;15:63–71

    PubMed  CAS  Google Scholar 

  97. Wilson WR, Karchmer AW, Dajani AS, et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci staphylococci, and HACEK microorganisms. JAMA 1995;274:1706–1713

    Article  PubMed  CAS  Google Scholar 

  98. Moellering RC Jr, Wennersten C, Weinberg AN. Studies on antibiotic synergism against enterococci I. Bacteriologic studies. J Lab Clin Med 1971;77:821–828

    CAS  Google Scholar 

  99. Wilson WR, Wilkowske CJ, Wright AJ, Sande MA, Geraci JE. Treatment of streptomycin-susceptible and streptomycin-resistant enterococcal endocarditis. Ann Intern Med 1984;100:816–823

    PubMed  CAS  Google Scholar 

  100. Koenig MG, Kaye D. Enterococcal endocarditis:report of nineteen cases with long-term follow-up data. N Engl J Med 1961;264:257–264

    Article  PubMed  CAS  Google Scholar 

  101. Morris JT, Cooper RH. Intravenous streptomycin:a useful route of administration. Clin Infect Dis 1994;19:1150–1151

    PubMed  CAS  Google Scholar 

  102. Rice LB, Calderwood SB, Eliopoulos GM, Farber BF, Karchmer AW. Enterococcal endocarditis:a comparison of prosthetic and native valve disease. Rev Infect Dis 1991;13:1–7

    PubMed  CAS  Google Scholar 

  103. Fantin B, Carbon C. Importance of the aminoglycoside dosing regimen in the penicillin-netilmicin combination for treatment of Enterococcus faecalis-induced experimental endocarditis. Antimicrob Agents Chemother 1990;34:2387–2391

    PubMed  CAS  Google Scholar 

  104. Marangos MN, Nicolau DP, Quintiliani R, Nightingale CH. Influence of gentamicin dosing interval on the efficacy of penicillin-containing regimens in experimental Enterococcus faecalis endocarditis. J Antimicrob Chemother 1997;39:519–522

    Article  PubMed  CAS  Google Scholar 

  105. Tam VH, Mckinnon PS, Levine DP, Brandel SM, Rybak MJ. Once-daily aminoglycoside in the treatment of Enterococcus faecalis endocarditis:case report and review. Pharmacotherapy 2000;20(9):1116–1119

    Article  PubMed  CAS  Google Scholar 

  106. Lee PYC, Das SS, Stevens PJ. Achieving bactericidal therapy and high-level aminoglycoside resistance. J Antimicrob Chemother 1993;31:608–609

    Article  PubMed  CAS  Google Scholar 

  107. Sacher HL, Miller WC, Landau SW, Sacher ML, Dixon WA, Dietrich KA. Relapsing native-valve enterococcal endocarditis:a unique cure with oral ciprofloxacin combination drug therapy. J Clin Pharmacol 1991;31:719–721

    PubMed  CAS  Google Scholar 

  108. Olaison L, Schadewitz K; Swedish Society of Infectious Diseases Quality Assurance Study Group for Endocarditis. Enterococcal endocarditis in Sweden, 1995–1999:can shorter therapy with aminoglycosides be used? Clin Infect Dis 2002;34:159–166

    Article  PubMed  Google Scholar 

  109. Ang JY, Lua JL, Turner DR, Asmar BI. Vancomycin-resistant Enterococcus faecium in a premature infant successfully treated with linezolid. Pediatr Infect Dis J 2003;22:1101–1103

    Article  PubMed  Google Scholar 

  110. Archuleta S, Murphy B, Keller MJ. Successful treatment of vancomycin-resistant Enterococcus faecium endocarditis with linezolid in a renal transplant recipient with human immunodeficiency virus infection. Transpl Infect Dis 2004;6:117–119

    Article  PubMed  CAS  Google Scholar 

  111. Babcock HM, Ritchie DJ, Christiansen E, Starlin R, Little R, Stanley S. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. Clin Infect Dis 2001;32:1373–1375

    Article  PubMed  CAS  Google Scholar 

  112. Bishara J, Sagie A, Samra Z, Pitlik S. Polymicrobial endocarditis caused by methicillin resistant-Staphylococcus aureus and glycopeptide-resistant enterococci. Eur J Clin Microbiol Infect Dis 1999;18:674–675

    Article  PubMed  CAS  Google Scholar 

  113. Bohta PL, Struwig MC, de Vreis W, Hough J, Chalkey LJ. Enterococcal endocarditis & a case treated with teicoplanin and amoxycillin. S Afr Med J 1998;88:564–565

    Google Scholar 

  114. Brink AJ, van den Ende J, Routier RJ, Devenish L. A case of vancomycin-resistant enterococcal endocarditis. S Afr Med J 2000;90:1113–1115

    PubMed  CAS  Google Scholar 

  115. Carfanga P, Tarasi A, Cassne M, Del Grosso MF, Bianco G, Venditti M. Prosthetic biologic valve endocarditis caused by a vancomycin-resistant (vanA) Enterococcus faecalis:case report. J Chemother 2000;12:416–420

    Google Scholar 

  116. Chien JW, Kucia ML, Salata RA. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clin Infect Dis 2000;30:146–151

    Article  PubMed  CAS  Google Scholar 

  117. Furlong WB, Rakowski TA. Therapy with RP 59500 (quinupristin/ dalfopristin) for prosthetic valve endocarditis due to enterococci with vanA/vanB resistance patterns. Clin Infect Dis 1997;25:163–164

    Article  PubMed  CAS  Google Scholar 

  118. Kapur D, Dorsky D, Feingold JM, et al. Incidence and outcome of vancomycin-resistant Enterococcal bacteremia following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2000;25:147–152

    Article  PubMed  CAS  Google Scholar 

  119. Matsumura S, Simor AE. Treatment of endocarditis due of vancomycin-resistant Enterococcus faecium with quinupristin/ dalfopristin, doxycycline, and rifampin:a synergistic drug combination. Clin Infect Dis 1998;27:1554–1556

    Article  PubMed  CAS  Google Scholar 

  120. Paterson DL, Dominguez EA, Chang F-Y, Snydman DR, Singh N. Infective endocarditis in solid organ transplant patients. Clin Infect Dis 1998;26:689–694

    Article  PubMed  CAS  Google Scholar 

  121. Thompson RL, Lavin B, Talbot GH. Endocarditis due to van-comycin-resistant Enterococcus faecium in an immunocompromised patient:cure by administering combination therapy with quinupristin—dalfopristin and high-dose ampicillin. South Med J 2003;96:818–820

    Article  PubMed  Google Scholar 

  122. Tiong I Y, Novaro GM, Jefferson B, Monson M, Smedira N, Penn MS. Bacterial endocarditis and functional mitral stenosis:a report of two cases and literature review. Chest 2002;122:2259–2262

    Article  PubMed  Google Scholar 

  123. Tripodi MF, Locatelli A, AdinolfiLE, Andreana A, Utili R. Successful treatment with ampicillin and fluoroquinolones of human endocarditis due to high-level gentamicin-resistant enterococci. Eur J Clin Microbiol Infect Dis 1998;17:734–736

    Article  PubMed  CAS  Google Scholar 

  124. Venditti M, Biavasco F, Varaldo PE, et al. Catheter related endocarditis due to glycopeptide-resistant Enterococcus faecalis in a transplanted heart. Clin Infect Dis 1993;17:524–5164a

    PubMed  CAS  Google Scholar 

  125. Vijayvargiya R, Veis JH. Antibiotic-resistant endocarditis in a hemodialysis patient. J Am Soc Nephrol 1996;7:536–542

    PubMed  CAS  Google Scholar 

  126. Wareham DW, Abbas H, Karcher AM, Das SS. Treatment of prosthetic valve infective endocarditis due to multi-resistant Gram-positive bacteria with linezolid. J Infect 2006;52:300–304

    Article  PubMed  CAS  Google Scholar 

  127. Yelamanchili S, Cunliffe NA, Miles RS. Prosthetic valve endocarditis caused by a vancomycin-resistant Enterococcus faecalis. J Infect Dis 1998;36:348–349

    CAS  Google Scholar 

  128. Sandoe JA, Witherden IR, Au-Yeung HK, Kite P, Kerr KG, Wilcox MH. Enterococcal intravascular catheter-related bloodstream infection:management and outcome of 61 consecutive cases. J Antimicrob Chemother 2002;50(4):577–582

    Article  PubMed  CAS  Google Scholar 

  129. Bayer AS, Seidel JS, Yoshikawa TT, Anthony BF, Guze LB. Group D enterococcal meningitis:clinical and therapeutic considerations with report of three cases and review of the literature. Arch Intern Med 1976;136:883–886

    Article  PubMed  CAS  Google Scholar 

  130. Stevenson KB, Murray EW, Sarubbi FA. Enterococcal meningitis:report of four cases and review. Clin Infect Dis 1994;18:233–239

    PubMed  CAS  Google Scholar 

  131. Krcméry V Jr, Filka J, Uher J, et al. Ciprofloxacin in treatment of nosocomial meningitis in neonates and in infants:report of 12 cases and review. Diagn Microb Infect Dis 1999;35:75–80

    Article  Google Scholar 

  132. Gransden WR, King A, Marossy D, Rosenthal E. Quinupristin/ dalfopristin in neonatal Enterococcus faecium meningitis. Arch Dis Child Fetal Neonatal Ed 1998;78:F235–F236

    Article  PubMed  CAS  Google Scholar 

  133. Losonsky GA, Wolf A, Schwalbe RS, Nataro J, Gibson CB, Lewis EW. Successful treatment of meningitis due to multiple resistant Enterococcus faecium with a combination of intrathecal teicoplanin and intravenous antimicrobial agents. Clin Infect Dis 1994;19:163–165

    PubMed  CAS  Google Scholar 

  134. Tush GM, Huneycutt S, Phillips A, Ward JD. Intraventricular quinupristin/dalfopristin for the treatment of vancomycin-re-sistant Enterococcus faecium shunt infection. Clin Infect Dis 1998;26:1460–1461

    Article  PubMed  CAS  Google Scholar 

  135. Zeana C, Kubin CJ, Della-Latta P, Hammer SM. Vancomycinresistant Enterococcus faecium meningitis successfully managed with linezolid:case report and review of the literature. Clin Infect Dis 2001;33:477–482

    Article  PubMed  CAS  Google Scholar 

  136. Hachem R, Afif C, Gokasian Z, Raad I. Successful treatment of vancomycin-resistant Enterococcus meningitis with linezolid. Eur J Clin Microbiol Infect Dis 2001;20:432–434

    Article  PubMed  CAS  Google Scholar 

  137. Moellering RC Jr. The enterococcus:a classic example of the impact of antimicrobial resistance on therapeutic options. J Antimicrob Chemother 1991;28:1–12

    Article  PubMed  Google Scholar 

  138. Kaye D. Treatment of infective endocarditis. Ann Intern Med 1996;124:606–608

    PubMed  CAS  Google Scholar 

  139. Thauvin C, Eliopoulos GM, Willey S, Wennersten C, Moellering RC Jr. Continuous-infusion ampicillin therapy of enterococcal endocarditis in rats. Antimicrob Agents Chemother 1989;31:139–143

    Google Scholar 

  140. Antony SJ, Ladner J, Stratton CW, Raudales F, Drummer SJ. High-level aminoglycoside-resistant enterococcus causing endocarditis successfully treated with a combination of ampicillin, imipenem and vancomycin. Scand J Infect Dis 1997;29:628–630

    Article  PubMed  CAS  Google Scholar 

  141. Antony SJ, Matheren P, Stratton CW. Increased bactericidal activity as documented by serum bactericidal titers for a triple combination of cell wall active agents against gentamicin-resistant enterococci. Scand J Infect Dis 1995;27:401–403

    Article  PubMed  CAS  Google Scholar 

  142. Foulds G. Pharmacokinetics of sulbactam/ampicillin in humans:a review. Rev Infect Dis 1986;8(Suppl 5):S503–S511

    PubMed  CAS  Google Scholar 

  143. Physicians' Desk Reference. 51st ed. Montvale, NJ:Medical Economics Company, Inc., 1997:2035

    Google Scholar 

  144. Dodge RA, Daly JS, Davaro R, Glew RH. High-dose ampicillin plus streptomycin for treatment of a patient with severe infection due to multiresistant enterococci. Clin Infect Dis 1997;25:1269–1270

    Article  PubMed  CAS  Google Scholar 

  145. Mekonen ET, Noskin GA, Hacek DM, Peterson LR. Successful treatment of persistent bacteremia due to vancomycin-resistant, ampicillin-resistant Enterococcus faecium. Microb Drug Resist 1995;1:249–253

    Article  PubMed  CAS  Google Scholar 

  146. Schmit JL. Efficacy of teicoplanin for enterococcal infections:63 cases and review. Clin Infect Dis 1992;15:302–306

    PubMed  CAS  Google Scholar 

  147. Presterl E, Graninger W, Georgopoulos A. The efficacy of teicoplanin in the treatment of endocarditis caused by Gram-positive bacteria. J Antimicrob Chemother 1993;31:755–766

    Article  PubMed  CAS  Google Scholar 

  148. Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000;342:710–721

    Article  PubMed  CAS  Google Scholar 

  149. Norris AH, Reilly JP, Edelstein PH, Brennan PJ, Schuster MG. Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections. Clin Infect Dis 1995;20:1137–1144

    PubMed  CAS  Google Scholar 

  150. Papanicolaou GA, Meyers RR, Meyers J, et al. Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients:risk factors for acquisition and mortality. Clin Infect Dis 1996;23:760–766

    PubMed  CAS  Google Scholar 

  151. Lam S, Singer C, Tucci V, Morthland VH, Pfaller MA, Isenberg HD. The challenge of vancomycin-resistant enterococci:a clinical and epidemiologic study. Am J Infect Control 1995;23:170–180

    Article  PubMed  CAS  Google Scholar 

  152. Lautenbach E, Schuster MG, Bilker WB, Brennan PJ. The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus. Clin Infect Dis 1998;27:1259–1265

    Article  PubMed  CAS  Google Scholar 

  153. Lynch C, Courvalin P, Nikaido H. Active efflux of antimicrobial agents in wild-type strains of enterococci. Antimicrob Agents Chemother 1997;41:869–871

    PubMed  CAS  Google Scholar 

  154. Moreno F, Jorgensen JH, Weiner MH. An old antibiotic for a new multiple-resistant Enterococcus faecium? Diagn Microbiol Infect Dis 1994;20:41–43

    Article  PubMed  CAS  Google Scholar 

  155. Howe RA, Robson M, Oakhill A, Cornish JM, Millar MR. Successful use of tetracycline as therapy of an immunocompromised patient with septicaemia caused by a vancomycin-resistant enterococcus. J Antimicrob Chemother 1997;40:144–145

    Article  PubMed  CAS  Google Scholar 

  156. Dever LL, Smith SM, DeJesus D, et al. Treatment of van-comycin-resistant Enterococcus faecium infections with an investigational streptogramin antibiotic (quinupristin/dalfopristin):a report of fifteen cases. Microbial Drug Resist 1996;2:407–413

    Article  CAS  Google Scholar 

  157. Linden PK, Pasculle AW, McDevitt D, Kramer DJ. Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia:comparison with a control cohort. J Antimicrob Chemother 1997;39(Suppl A):145–151

    Article  PubMed  CAS  Google Scholar 

  158. Winston DJ, Emmanouilides C, Kroeber A, et al. Quinupristin/ dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium. Clin Infect Dis 2000;30:790–797

    Article  PubMed  CAS  Google Scholar 

  159. Moellering RC, Linden PK, Reinhardt J, Blumberg EA, Bompart F, Talbot GH. The efficacy and safety of quinupristin/ dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother 1999;44:251–261

    Article  PubMed  CAS  Google Scholar 

  160. Eliopoulos GM. Quinupristin—Dalfopristin and linezolid:evidence and opinion. Clin Infect Dis 2003;36:473–481

    Article  PubMed  Google Scholar 

  161. Lai KK. Treatment of vancomycin-resistant Enterococcus faecium infections. Arch Intern Med 1996;156:2579–2584

    Article  PubMed  CAS  Google Scholar 

  162. Nachtman A, Verma R, Egnor M. Vancomycin-resistant Enterococcus faecium shunt infection in an infant:an antibiotic cure. Microbial Drug Resist 1995;1:95–96

    Article  Google Scholar 

  163. Sahgal VS, Urban C, Mariano N, Weinbaum F, Turner J, Rahal JJ. Quinupristin/dalfopristin (RP 59500) therapy for vancomycinresistant Enterococcus faecium aortic graft infection:case report. Microbial Drug Resist 1995;1:245–247

    Article  CAS  Google Scholar 

  164. Tan T Y, Pitman I, Penrose-Stevens A, Simpson BA, Flanagan PG. Treatment of a vancomycin-resistant Enterococcus faecium ventricular drain infection with quinupristin/dalfopristin and review of the literature. J Infect 2000;41:85–97

    Article  Google Scholar 

  165. Patel RM, Rouse S, Piper KE, Steckelberg JM. Linezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditis. Antimicrob Agents Chemother 2001;45:621–623

    Article  PubMed  CAS  Google Scholar 

  166. Millichap J, Ristow RA, Noskin GA, Peterson LR. Selection of Enterococcus faecium strains with stable and unstable resistance to the streptogramin RP 59500 using stepwise in vitro exposure. Diagn Microbiol Infect Dis 1996;25:15–20

    Article  PubMed  CAS  Google Scholar 

  167. Aeschlimann JR, Zervos MJ, Rybak MJ. Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin— dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharma-codynamic infection model with simulated endocardial vegetations. Antimicrob Agents Chemother 1998;42(10):2710–2717

    PubMed  CAS  Google Scholar 

  168. Chow JW, Donabedian SM, Zervos MJ. Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia. Clin Infect Dis 1997;24:90–91

    PubMed  CAS  Google Scholar 

  169. Linden PK, Pasculle AW, Manez R, et al. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 1996;22:663–670

    PubMed  CAS  Google Scholar 

  170. Chow JW, Davidson A, Sanford E III, Zervos MJ. Superinfection with Enterococcus faecalis during quinupristin/dalfopristin therapy. Clin Infect Dis 1997;24:91–92

    PubMed  CAS  Google Scholar 

  171. Shinabarger DL, Marotti KR, Murray RW, et al. Mechanism of action of oxazolidinones:effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother 1997;41:2132–2136

    PubMed  CAS  Google Scholar 

  172. Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998;42:3251–3255

    PubMed  CAS  Google Scholar 

  173. Moellering RC. Linezolid:the first oxazolidinone antimicrobial. Ann Intern Med 2003;138:135–142

    PubMed  CAS  Google Scholar 

  174. Bostic GD, Perri MB, Thal LA, Zervos MJ. Comparative in vitro and bactericidal activity of oxazolidinone antibiotics against multidrug-resistant enterococci. Diagn Microbiol Infect dis 1996;173:909–913

    Google Scholar 

  175. Eliopoulos GM, Wennersten CB, Gold HS, Moellering RC Jr. In vitro activities of new oxazolidinone antimicrobial agents against enterococci. Antimicrob Agents Chemother 1996;40:1745–1747

    PubMed  CAS  Google Scholar 

  176. Ford CW, Hamel JC, Wilson DM, et al. invivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents against experimental bacterial infections. Antimicrob Agents Chemother 1996;40:1508–1513

    PubMed  CAS  Google Scholar 

  177. Noskin GA, Siddiqui F, Stosor V, Hacek D, Peterson LR. In vitro activities of linezolid against important Gram-positive bacterial pathogens including vancomycin-resistant enterococci. Antimicrob Agents Chemother 1999;43:2059–2062

    PubMed  CAS  Google Scholar 

  178. Patel R, Rouse MS, Piper KE, et al. In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Diagn Microbiol Infect Dis 1999;34:119–122

    Article  PubMed  CAS  Google Scholar 

  179. Rybak MJ, Cappelletty DM, Moldovan T, Aeschlimann JR, Kaatz GW. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium. Antimicrob Agents Chemother 1998;42:721–724

    Article  PubMed  CAS  Google Scholar 

  180. Schülin T, Thauvin-Eliopoulos C, Moellering RC Jr, Elipopulos GM. Activities of the oxazolidinones linezolid and eperezolid in experimental intraabdominal abscess due to Enterococcus faecalis or vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1999;43:2873–2876

    PubMed  Google Scholar 

  181. Noskin GA, Siddiqui F, Stosor V, Kruzynski J, Peterson LR. Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin. Clin Infect Dis 1999;28:689–690

    Article  PubMed  CAS  Google Scholar 

  182. McNeil SA, Clark NM, Chandrasekar PH, Kauffman CA. Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with Synercid (quinupristin/dalfopristin). Clin Infect Dis 2000;30:403–404

    Article  PubMed  CAS  Google Scholar 

  183. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, gram-positive infections:experience from a compassionate-use program. Clin Infect Dis 2003;36(2):159–168

    Article  PubMed  CAS  Google Scholar 

  184. Raad I, Hachem R, Hanna H, et al. Prospective, randomized study comparing quinupristin—dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. J Antimicrob Chemother 2004;53(4):646–649

    Article  PubMed  CAS  Google Scholar 

  185. Linden PK. Treatment options for vancomycin-resistant enterococcal infections. Drugs 2002;62(3):425–441

    Article  PubMed  CAS  Google Scholar 

  186. Rao N, White GJ. Successful treatment of Enterococcus faecalis prosthetic valve endocarditis with linezolid. Clin Infect Dis 2002;35(7):902–904

    Article  PubMed  Google Scholar 

  187. Zimmer SM, Caliendo AM, Thigpen MC, Somani J. Failure of linezolid treatment for enterococcal endocarditis. Clin Infect Dis 2003;37:e29–e30

    Article  PubMed  CAS  Google Scholar 

  188. Melzer M, Goldsmith D, Gransden W. Successful treatment of vertebral osteomyelitis with linezolid in a patient receiving hemodialysis and with persistent methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus bacteremias. Clin Infect Dis 2000;31:208–209

    Article  PubMed  CAS  Google Scholar 

  189. Rao N, Ziran BH, Hall RA, Santa ER. Successful treatment of chronic bone and joint infections with oral linezolid. Clin Orthop Relat Res 2004;427:67–71

    Article  PubMed  Google Scholar 

  190. Till M, Wixson RL, Pertel PE. Linezolid treatment for osteomyelitis due to vancomycin-resistant Enterococcus faecium. Clin Infect Dis 2002;34(10):1412–1414

    Article  PubMed  Google Scholar 

  191. Steinmetz MP, Vogelbaum MA, De Georgia MA, Andrefsky JC, Isada C. Successful treatment of vancomycin-resistant Enterococcus meningitis with linezolid:case report and review of the literature. Crit Care Med 2001;29(12):2383–2385

    Article  PubMed  CAS  Google Scholar 

  192. Zurenko GE, Todd WM, Hafkin B, et al. Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid [abstract]. Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, Sept 24–27, 1999. Washington, DC. American Society for Microbiology, 1999:118

    Google Scholar 

  193. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001;357:1179

    Article  PubMed  CAS  Google Scholar 

  194. Mutnick AH, Enne V, Jones RN. Linezolid resistance since 2001:SENTRY Antimicrobial Surveillance Program. Ann Pharmacother 2003;37:769–774

    Article  PubMed  CAS  Google Scholar 

  195. Dibo I, Pillai SK, Gold HS, et al. Linezolid-resistant Enterococcus faecalis isolated from a cord blood transplant recipient. J Clin Microbiol 2004;42(4):1843–1845

    Article  PubMed  Google Scholar 

  196. Burleson BS, Ritchie DJ, Micek ST, Dunne WM. Enterococcus faecalis resistant to linezolid:case series and review of the literature. Pharmacotherapy 2004;24(9):1225–1231

    Article  PubMed  Google Scholar 

  197. Carpenter CF, Chambers HF. Daptomycin:another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004;38(7):994–1000

    Article  PubMed  CAS  Google Scholar 

  198. Shah PM. The need for new therapeutic agents:what is the pipeline? Clin Microbiol Infect 2005;11(Suppl 3):36–42

    Article  PubMed  CAS  Google Scholar 

  199. Hsueh PR, Chen WH, Teng LJ, Luh KT. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003:resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents. Int J Antimicrob Agents 2005;26(1):43–49

    Article  PubMed  CAS  Google Scholar 

  200. Critchley IA, Draghi DC, Sahm DF, Thornsberry C, Jones Me, Karlowsky JA. Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000–2001. J Antimicrob Chemother 2003;51(3):639–649

    Article  PubMed  CAS  Google Scholar 

  201. Novais C, Sousa JC, Coque TM, Peixe LV. Portuguese Resistance Study Group. In vitro activity of daptomycin against enterococci from nosocomial and community environments in Portugal. J Antimicrob Chemother 2004;54(5):964–966

    CAS  Google Scholar 

  202. Johnson AP, Mushtaq S, Warner M, Livermore DM. Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid. Int J Antimicrob Agents 2004;24(4):315–319

    Article  PubMed  CAS  Google Scholar 

  203. Cha R, Rybak MJ. Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Diagn Microbiol Infect Dis 2003;47:539–546

    Article  PubMed  CAS  Google Scholar 

  204. Snydman DR, McDermott LA, Jacobus NV. Determination of synergistic effects of daptomycin with gentamicin or in vitro effect of beta-lactam antibiotics against Staphylococcus aureus and enterococci by FIC index and time kill kinetics. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy 2001; Dec 16–19; Chicago, IL, Abstract no. E-533

    Google Scholar 

  205. Silverman JA, Oliver N, Andrew T, Li T. Resistance studies with daptomycin. Antimicrob Agents Chemother 2001;45(6):1799–1802

    Article  PubMed  CAS  Google Scholar 

  206. Lewis JS II, Owens A, Cadena J, Sabol K, Patterson JE, Jorgensen JH. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother 2005;49(4):1664–1665

    Article  PubMed  CAS  Google Scholar 

  207. Munoz-Price LS, Lolans K, Quinn JP. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection. Clin Infect Dis 2005;41(4):565–566

    Article  PubMed  Google Scholar 

  208. Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after a single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005;49:220–229

    Article  PubMed  CAS  Google Scholar 

  209. Noskin GA. Tigecycline:a new glycylcycline for treatment of serious infection. Clin Infect Dis 2005;41:S303–S314

    Article  PubMed  CAS  Google Scholar 

  210. Stein GE. Safety of the newer parenteral antibiotics. Clin Infect Dis 2005;41:S293–S302

    Article  PubMed  CAS  Google Scholar 

  211. Levine DP, Holley HP, Eiseman I, Willcox P, Tack K. Clinafloxacin for the treatment of bacterial endocarditis. Clin Infect Dis 2004;38:620–631

    Article  PubMed  CAS  Google Scholar 

  212. Shah P, Trostmann U, Tack K. Open-label, multicentre, emergency-use study of clinafloxacin (CI-960) in the treatment of patients with serious life-threatening infections. Int J Antimicrob Agents 2002;19:245–248

    Article  PubMed  CAS  Google Scholar 

  213. Tack KJ, Eiseman I, Zervos MJ. Clinafloxacin in serious infections caused by multiply resistant pathogens. Drugs 1999;58:260–262

    Article  CAS  Google Scholar 

  214. Streit JM, Fritsche TR, Sader HS, Jones RN. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect Dis 2004;48:137–143

    Article  PubMed  CAS  Google Scholar 

  215. Malabarba A, Goldstein BP. Origin, structure, and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemo 2005;55:ii15–ii20

    Article  CAS  Google Scholar 

  216. Guay DRP. Dalbavancin:an investigational glycopeptide. Expert Rev Anti Infect Ther 2004;2:845–852

    Article  PubMed  CAS  Google Scholar 

  217. Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis 2005;40:374–380

    Article  PubMed  CAS  Google Scholar 

  218. Inoue M, Nonoyama M, Okamoto R, Ida T. Antimicrobial activity of arbekacin, a new aminoglycoside antibiotic, against methicillin-resistant Staphylococcus aureus. Drugs Exp Clin Res 1994;22:233–240

    Google Scholar 

  219. Kak V, Donabedian SM, Zervos MJ, Kariyama R, Kumon H, Chow JW. Efficacy of ampicillin plus arbekacin in experimental rabbit endocarditis caused by an Enterococcus faecalis strain with high-level gentamicin resistance. Antimicrob Agents Chemother 2000; 44:2545–2546

    Article  PubMed  CAS  Google Scholar 

  220. Kak V, You I, Zervos MJ, Kariyama R, Kumon H, Chow JW. In-vitro synergistic activity of the combination of ampicillin and arbekacin against vancomycin- and high-level gentamicinresistant Enterococcus faecium with the aph(2′)-Id gene. Diagn Microbiol Infect Dis 2000;37:297–299

    Article  PubMed  CAS  Google Scholar 

  221. Osakabe Y, Takahashi Y, Narihara K. The utility and dosage and administration of arbekacin in patients with MRSA infection. Antibiot Chemother 1996;12:120–127

    Google Scholar 

  222. Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 1995;44(RR-12):1–13

    Google Scholar 

  223. Hachem R, Raad I. Failure of oral antimicrobial agents in eradicating gastrointestinal colonization with vancomycinresistant enterococci. Infect Control Hosp Epidemiol 2002; 23:43–44

    Article  PubMed  Google Scholar 

  224. Livornese LL Jr, Dias S, Samel C, et al. Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers. Ann Intern Med 1992;117:112–116

    PubMed  Google Scholar 

  225. Bonilla HF, Zervos MJ, Kauffman CA. Long term survival of vancomycin-resistant Enterococcus faecium on a contaminated surface. Infect Control Hosp Epidemiol 1996;17(12):770–772

    Article  PubMed  CAS  Google Scholar 

  226. Oprea SF, Zaidi N, Donabedian SM, Balasubramaniam M, Hershberger E, Zervos MJ. Molecular and clinical epidemiology of vancomycin-resistant Enterococcus faecalis. J Antimicrob Chemother 2004;53:626–630

    Article  PubMed  CAS  Google Scholar 

  227. Ostrowsky BE, Trick WE, Sohn AH, et al. Control of vancomycin-resistant enterococcus in health care facilities in a region. N Engl J Med 2001; 344:1427–1433

    Article  PubMed  CAS  Google Scholar 

  228. Donabedian S, Hershberger E, Thal LA, et al. PCR fragment length polymorphism analysis of vancomycin-resistant Enterococcus faecium. J Clin Microbiol 2000;38:2885–2888

    PubMed  CAS  Google Scholar 

  229. Peterson LR, Noskin GA. New technology for detecting multidrug-resistant pathogens in the clinical microbiology laboratory. Emerg Infect Dis 2001;7:1–12

    Article  Google Scholar 

  230. Peterson LR, Petzel RA, Clabots CR, Fasching CE, Gerding DN. Medical technologists using molecular epidemiology as part of the infection control team. Diagn Microbiol Infect Dis 1993;16:303–311

    Article  PubMed  CAS  Google Scholar 

  231. Singh P, Goering RV, Simjee S, Foley SL, and Zervos MJ. Application of molecular techniques to the study of hospital infection. Clin Microbiol Rev 2006;19:512–530

    Article  PubMed  CAS  Google Scholar 

  232. Flannagan SE, Chow JW, Donabedian SM, et al. Plasmid content of a vancomycin-resistant Enterococcus faecalis isolate from a patient also colonized by Staphylococcus aureus with a VanA phenotype. Antimicrob Agents Chemother 2003;47:3954–3959

    Article  PubMed  CAS  Google Scholar 

  233. Sadfar AJ, Bryan CS, Stinson S, Saunders DE. Prosthetic valve endocarditis due to vancomycin resistant Enterococcus faecium:treatment with chloramphenicol and minocycline. Clin Infect Dis 2002;34:61–63

    Article  Google Scholar 

  234. Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, et al., Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;335:653–665

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Henry Ford Health System, Wayne State University School of Medicine, Detroit, MI, USA

    Anne Y. Chen

  2. Division Head, Infectious Diseases, Henry Ford Health System, Wayne State University School of Medicine, Detroit, MI, USA

    Marcus J. Zervos

Authors
  1. Anne Y. Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marcus J. Zervos
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Executive Vice President & Chief Medical Officer, Idenix Pharmaceuticals, Cambridge, MA, USA

    Douglas L. Mayers MD

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Chen, A.Y., Zervos, M.J. (2009). Enterococcus: Antimicrobial Resistance in Enterococci Epidemiology, Treatment, and Control. In: Mayers, D.L. (eds) Antimicrobial Drug Resistance. Infectious Disease. Humana Press. https://doi.org/10.1007/978-1-60327-595-8_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-595-8_3

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60327-594-1

  • Online ISBN: 978-1-60327-595-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation